Overview
Financials
Units: $M (per-share in $, ratios in %)Revenue & profit
Margins
Valuation
Multiples at each fiscal year end (annual) and current (TTM)Valuation history
Segments
Revenue breakdown (annual, $B). Segments depend on each year’s disclosure.By product
By region
Dividends & earnings
Annual dividend per share ($, split-adjusted)
EPS (diluted), last 16 quarters ($)
Company info
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company focused on developing ready-to-use, precision T cell therapies. Their research and development efforts span virology, oncology, and neurological conditions. The company's flagship experimental treatment, TVGN 489, is a precision T cell product designed to meet the unmet needs of individuals severely affected by acute COVID-19, as well as a specific group of patients struggling with long COVID. Tevogen Bio Holdings Inc. is headquartered in Warren, New Jersey.